Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa

被引：0
|
作者：
Dimova, Rositsa B.
Talal, Andrew H. [1 ]
机构：
[1] Weill Cornell Med Coll, Ctr Study Hepatitis C, New York, NY 10065 USA
来源：
JOURNAL OF HEPATOLOGY | 2010年 / 53卷 / 03期
关键词：
HEPATITIS-C VIRUS; INFECTED PATIENTS; HCV; RIBAVIRIN; KINETICS; HIV; RESPONSES; EFFICACY; DYNAMICS; THERAPY;
D O I：
10.1016/j.jhep.2010.04.014
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：418 / 420
页数：3
相关论文
共 50 条
  • [31] Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response
    Zeuzem, Stefan
    Poordad, Fred
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (07) : 1733 - 1743
  • [32] Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview
    Jeon, Jae Yoon
    Ayyar, Vivaswath S.
    Mitra, Amitava
    PHARMACEUTICAL RESEARCH, 2022, 39 (08) : 1749 - 1759
  • [33] Nitric Oxide Levels and Sustained Virological Response to Pegylated-Interferon alpha2a plus Ribavirin in Chronic HCV Genotype 4 Hepatitis: a Prospective Study
    Ibrahim, Mohamed
    Gomaa, Wafaey
    Ibrahim, Yehia
    El Hadad, Hazem
    Shatat, Mohamed
    Aleem, Ashraf Abdel
    Essawy, Mohamed
    Fouad, Yasser M.
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2010, 19 (04) : 387 - 392
  • [34] Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study
    Suda, Goki
    Ito, Jun
    Nagasaka, Atsushi
    Yamamoto, Yoshiya
    Furuya, Ken
    Okamoto, Munenori
    Terashita, Katsumi
    Kobayashi, Tomoe
    Tsunematsu, Izumi
    Yoshida, Junichi
    Meguro, Takashi
    Ohara, Masatsugu
    Kawagishi, Naoki
    Kimura, Megumi
    Umemura, Machiko
    Izumi, Takaaki
    Tsukuda, Yoko
    Nakai, Masato
    Sho, Takuya
    Natsuizaka, Mitsuteru
    Morikawa, Kenichi
    Ogawa, Koji
    Sakamoto, Naoya
    HEPATOLOGY RESEARCH, 2018, 48 (03) : E146 - E154
  • [35] HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a
    Lange, Christian M.
    Susser, Simone
    Herrmann, Eva
    Karey, Ursula
    Kieffer, Tara L.
    Kwong, Ann D.
    Schinkel, Janke
    Reesink, Henk W.
    Zeuzem, Stefan
    Sarrazin, Christoph
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2011, 46 (11) : 1362 - 1368
  • [36] Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab Ozogamicin
    Fostvedt, Luke K.
    Hibina, Jennifer E.
    Masters, Joanna C.
    Vandendries, Erik
    Ruiz-Garcia, Ana
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (05) : 1006 - 1017
  • [37] Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera
    Gangaraju, Radhika
    Kim, Soo J.
    Dong, Jing-Fei
    Swierczek, Sabina
    Prchal, Josef T.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (06): : 757 - 760
  • [38] Pegylated Interferon Alfa-2B for Chronic Delta Hepatitis: 12 versus 24 Months
    Ormeci, Necati
    Bolukbas, Fusun
    Erden, Esra
    Coban, Sahin
    Ekiz, Fuat
    Erdem, Hakan
    Palabiyikoglu, Murat
    Beyler, Ali Resit
    Balik, Ismail
    Bolukbas, Cengiz
    Nazligul, Yasar
    Koklu, Seyfettin
    HEPATO-GASTROENTEROLOGY, 2011, 58 (110) : 1648 - 1653
  • [39] Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review
    Stiefel, Hillary C.
    Kopplin, Laura J.
    Albini, Thomas
    Chang, Michael
    Vegunta, Sravanthi
    Suhler, Eric B.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2021, 29 (03) : 566 - 571
  • [40] Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis
    Hartwell, Debbie
    Shepherd, Jonathan
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 (01) : 56 - 62
12345